Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Johnson and Johnson
AstraZeneca
Moodys
Dow

Last Updated: January 21, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for MGB-BP-3


Email this page to a colleague

« Back to Dashboard

What is the drug development status for MGB-BP-3?

MGB-BP-3 is an investigational drug.

There have been 5 clinical trials for MGB-BP-3. The most recent clinical trial was a Phase 2 trial, which was initiated on January 15th 2019.

The most common disease conditions in clinical trials are Clostridium Infections, Hypertension, and Vomiting. The leading clinical trial sponsors are MGB Biopharma Limited, Hammersmith Medicines Research, and Innovate UK.

There are two US patents protecting this investigational drug and twenty international patents.

Recent Clinical Trials for MGB-BP-3
TitleSponsorPhase
Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDADSyneos HealthPhase 2
Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDADMGB Biopharma LimitedPhase 2
MR Antagonist and STRIATINBrigham and Women's HospitalPhase 4

See all MGB-BP-3 clinical trials

Clinical Trial Summary for MGB-BP-3

Top disease conditions for MGB-BP-3
Top clinical trial sponsors for MGB-BP-3

See all MGB-BP-3 clinical trials

US Patents for MGB-BP-3

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MGB-BP-3 ⤷  Try it Free Halogenated salicylanilides for treating clostridium infections UNION therapeutics A/S (Hellerup, DK) ⤷  Try it Free
MGB-BP-3 ⤷  Try it Free Minor groove binders University of Strathclyde (Glasgow, GB) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MGB-BP-3

Drugname Country Document Number Estimated Expiration Related US Patent
MGB-BP-3 China CN107847507 2035-05-29 ⤷  Try it Free
MGB-BP-3 China CN113368116 2035-05-29 ⤷  Try it Free
MGB-BP-3 European Patent Office EP3302492 2035-05-29 ⤷  Try it Free
MGB-BP-3 United Kingdom GB201509326 2035-05-29 ⤷  Try it Free
MGB-BP-3 Japan JP2018517770 2035-05-29 ⤷  Try it Free
MGB-BP-3 Japan JP6873110 2035-05-29 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Johnson and Johnson
AstraZeneca
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.